Upregulation of transferrin receptor 2 and ferroportin 1 mRNA in the liver of patients with chronic hepatitis C

Journal of Gastroenterology and Hepatology (Australia)

Volumn 20, Issue 4, 2005, Pages 562-569

  Takeo, Masaki ^a   Kobayashi, Yoshinao ^a,b   Fujita, Naoki ^a   Urawa, Naohito ^a   Iwasa, Motoh ^a   Horiike, Shinichiro ^a   Tanaka, Hideaki ^a   Kaito, Masahiko ^a   Adachi, Yukihiko ^a  

^a MIE UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NONE   (Japan)

Author keywords

Hepatitis C virus; Iron; Total hepatic iron score

Indexed keywords

CD71 ANTIGEN; FERRIC FERROCYANIDE; FERROPORTIN 1; INTERFERON; IRON; MESSENGER RNA; TRANSFERRIN RECEPTOR; TRANSFERRIN RECEPTOR 2; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ACTIVITY; DISEASE COURSE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN TISSUE; IRON TRANSPORT; LIVER; LIVER BIOPSY; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

EID: 19944372054     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2005.03770.x     Document Type: Article

References (34)

1. Bonkovsky HL, Banner BF, Rothman AL. Iron and chronic viral hepatitis. Hepatology 1997; 25: 759-68.
2. Klausner RD, Rouault TA, Harford JB. Regulating the fate of mRNA: the control of cellular iron metabolism. Cell 1993; 72: 19-28.
3. Britton RS, Bacon BR. Role of free radicals in liver diseases and hepatic fibrosis. Hepatogastroenterology 1994; 41: 343-8.
4. Kato J, Kobune M, Nakamura T et al. Normalization of elevated hepatic 8-hydroxy-2′-deoxyguanosine levels in chronic hepatitis C patients by phlebotomy and low iron diet. Cancer Res. 2001; 61: 8697-702.
5. Di Bisceglie AM, Axiotis CA, Hoofnagle JH et al. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992; 102: 2108-13.
6. Farinati F, Cardin R, De Maria N et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J. Hepatol. 1995; 22: 449-56.
7. Isomura T, Yano M, Hayashi H et al. Excess iron in the liver of patients with chronic hepatitis C. J. Clin. Electron Microsc. 1992; 25: 231-7.
8. Yano M, Hayashi H, Wakusawa S et al. Hepatic iron storage in patients with chronic hepatitis C but no hepatic iron detectable histochemically. Med. Electron Microsc. 1997; 30: 70-5.
9. Bassett SE, Di Bisceglie AM, Bacon BR et al. Effects of iron loading on pathogenicity in hepatitis C virus-infected chimpanzees. Hepatology 1999; 29: 1884-92.
10. Piperno A, Sampietro M, D'Alba R et al. Iron stores, response to alpha-interferon therapy, and effects of iron depletion in chronic hepatitis C. Liver 1996; 16: 248-54.
11. Olynyk JK, Reddy KR, Di Bisceglie AM et al. Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C. Gastroenterology 1995; 108: 1104-9.
12. Hayashi H, Takikawa T, Nishimura N et al. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am. J. Gastroenterol. 1994; 89: 986-8.
13. Hayashi H, Takikawa T, Nishimura N et al. Serum aminotransferase levels as an indicator of the effectiveness of venesection for chronic hepatitis C. J. Hepatol. 1995; 22: 268-71.
14. Iwasa M, Kaito M, Ikoma J et al. Dietary iron restriction improves aminotransferase levels in chronic hepatitis C patients. Hepatogastroenterology 2002; 49: 529-31.
15. Kawabata H, Yang R, Hirama T et al. Molecular cloning of transferrin receptor 2. A new member of the transferrin receptor-like family. J. Biol. Chem. 1999; 274: 20826-32.
16. Lee PL, Halloran C, West C et al. Mutation analysis of the transferrin receptor-2 gene in patients with iron overload. Blood Cells Mol. Dis. 2001; 27: 285-9.
17. Girelli D, Bozzini C, Roetto A et al. Clinical and pathologic findings in hemochromatosis type 3 due to a novel mutation in transferrin receptor 2 gene. Gastroenterology 2002; 122: 1295-302.
18. Roetto A, Totaro A, Piperno A et al. New mutations inactivating transferrin receptor 2 in hemochromatosis type 3. Blood 2001; 97: 2555-60.
19. Hattori A, Wakusaka S, Hayashi H et al. AVAQ 594-597 deletion of the TfR2 gene in Japanese family with hemochromatosis. Hepatol. Res. 2003; 26: 154-6.
20. Zhang AS, Xiong S, Tsukamoto H, Enns CA. Localization of iron metabolism-related mRNAs in rat liver indicate that HFE is predominantly expressed in hepatocytes. Blood 2004; 103: 1509-14.
21. Jouanolle AM, Douabin-Gicquel V, Halimi C et al. Novel mutation in ferroportin 1 gene is associated with autosomal dominant iron overload. J. Hepatol. 2003; 39: 286-9.
22. Rivard SR, Lanzara C, Grimard D et al. Autosomal dominant reticuloendothelial iron overload (HFE type 4) due to a new missense mutation in the FERROPORTIN 1 gene (SLC11A3) in a large French-Canadian family. Haematologica 2003; 88: 824-6.
23. Donovan A, Brownlie A, Zhou Y et al. Positional cloning of zebrafish ferroportin1 identifies a conserved vertebrate iron exporter. Nature 2000; 403: 776-81.
24. Gibson UE, Heid CA, Williams PM. A novel method for real time quantitative RT-PCR. Genome Res. 1996; 6: 995-1001.
25. Heid CA, Stevens J, Livak KJ, Williams PM. Real time quantitative PCR. Genome Res. 1996; 6: 986-94.
26. Rigler R, Foldes-Papp Z, Meyer-Almes FJ et al. Fluorescence cross-correlation: a new concept for polymerase chain reaction. J. Biotechnol. 1998; 63: 97-109.
27. Chiang PW, Song WJ, Wu KY et al. Use of a fluorescent-PCR reaction to detect genomic sequence copy number and transcriptional abundance. Genome Res. 1996; 6: 1013-26.
28. Ichida F, Tsujii T, Omata M. New Inuyama classification: new criteria for histological assessment of chronic hepatitis. Int. Hepatol. Commun. 1996; 6: 112-19.
29. Barton AL, Banner BF, Cable EE et al. Distribution of iron in the liver predicts the response of chronic hepatitis C infection to interferon therapy. Am. J. Clin. Pathol. 1995; 103: 419-24.
30. Tuung BY, Emond MJ, Bronner MP, Raaka SD, Coder SJ, Kowdley KV. Hepatitis C, iron status, and disease severity: relationship with HFE mutations. Gastroenterology 2003; 124: 318-26.
31. Shiono Y, Ikeda R, Hayashi H et al. C282Y and H63D mutations in the HFE gene have no effect on iron overload disorders in Japan. Intern. Med. 2001; 40: 852-6.
32. Kawabata H, Germain RS, Vuong PT et al. Transferrin receptor 2-alpha supports cell growth both in iron-chelated cultured cells and in vivo. J. Biol. Chem. 2000; 275: 16618-25.
33. Fleming RE, Ahmann JR, Migas MC et al. Targeted mutagenesis of the murine transferrin receptor-2 gene produces hemochromatosis. Proc. Natl Acad. Sci. USA 2002; 99: 10 653-8.
34. Scheiber-Mojdehkar B, Strum B, Plank L, Kryzer I, Goldberg H. Influence of parenteral iron preparations on non-transferrin bound iron uptake, the iron regulatory protein and the expression of ferritin and the divalent metal transporter DMT-1 in HepG2 human hepatoma cells. Biochem. Pharmacol. 2003; 65: 1973-8.